Immunome (NASDAQ:IMNM) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Immunome to “strong sell”, contrasting with the broader analyst consensus of “Moderate Buy.” Twelve analysts rate the stock Buy and one rates it Sell, with a consensus price target of $34.64.
• Immunome reported a quarterly loss of $0.65 per share, missing estimates by $0.14, and analysts expect a full-year loss of approximately $2.30 per share.
• Insiders sold 682,310 shares worth about $15.7 million over the past three months, while potential catalysts include the FDA’s review of the company’s varegacestat NDA and expected 2026 data from its IM-1021 program.

Immunome (NASDAQ:IMNM - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued to investors on Saturday.

Several other analysts have also recently commented on IMNM. Leerink Partners decreased their price objective on shares of Immunome from $37.00 to $33.00 and set an "outperform" rating for the company in a research note on Friday, May 15th. Truist Financial increased their price objective on shares of Immunome from $37.00 to $38.00 and gave the stock a "buy" rating in a research note on Wednesday. Wedbush raised their target price on shares of Immunome from $31.00 to $35.00 and gave the stock an "outperform" rating in a report on Wednesday. HC Wainwright restated a "buy" rating on shares of Immunome in a research report on Thursday, July 9th. Finally, Citigroup reaffirmed a "buy" rating on shares of Immunome in a report on Thursday, July 9th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $34.64.

Immunome Stock Performance

Shares of IMNM stock opened at $27.20 on Friday. Immunome has a fifty-two week low of $8.66 and a fifty-two week high of $28.62. The firm has a market capitalization of $3.09 billion, a PE ratio of -10.75 and a beta of 2.08. The stock's 50-day simple moving average is $22.20 and its 200-day simple moving average is $22.24.

Immunome (NASDAQ:IMNM - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.14). Sell-side analysts forecast that Immunome will post -2.3 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Robert Lechleider sold 55,000 shares of Immunome stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $19.85, for a total transaction of $1,091,750.00. Following the completion of the transaction, the insider directly owned 15,805 shares of the company's stock, valued at $313,729.25. The trade was a 77.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 101,050 shares of the business's stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00. Following the completion of the transaction, the director owned 308,504 shares of the company's stock, valued at approximately $6,515,604.48. This represents a 24.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 682,310 shares of company stock valued at $15,675,566. Insiders own 7.21% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Creative Planning raised its position in shares of Immunome by 4.0% in the third quarter. Creative Planning now owns 18,664 shares of the company's stock worth $219,000 after acquiring an additional 710 shares during the period. Russell Investments Group Ltd. grew its position in shares of Immunome by 14.4% during the 4th quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company's stock valued at $159,000 after acquiring an additional 935 shares during the period. Allworth Financial LP acquired a new stake in shares of Immunome during the 2nd quarter valued at about $25,000. California State Teachers Retirement System grew its position in shares of Immunome by 1.8% during the 4th quarter. California State Teachers Retirement System now owns 67,012 shares of the company's stock valued at $1,439,000 after acquiring an additional 1,167 shares during the period. Finally, Assetmark Inc. increased its stake in shares of Immunome by 46.6% in the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company's stock valued at $99,000 after purchasing an additional 1,442 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company's stock.

Key Immunome News

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Investors remain focused on the FDA’s acceptance of Immunome’s varegacestat NDA and an April 2027 PDUFA decision date. The company also expects initial 2026 data from its Phase 1 IM-1021 ROR1 antibody-drug conjugate program, providing potential catalysts for the stock. Immunome catalysts and Strong Buy analysis
• Positive Sentiment: HC Wainwright maintained a Buy rating and projects a potential transition to profitability over the longer term, forecasting positive EPS of $0.40 in fiscal 2029 and $1.08 in fiscal 2030. These estimates support the longer-term investment case despite current losses.
• Neutral Sentiment: Director Isaac Barchas sold shares under a pre-arranged Rule 10b5-1 plan, including 98,712 shares from August 10–12 for roughly $2.6 million. The planned nature of the transactions makes them a less definitive signal about management’s current outlook, although the sales may weigh on sentiment. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the consensus loss of $0.51. The earnings miss triggered a recent gap lower and highlights continued cash-burn and execution risks for the clinical-stage biotechnology company. Immunome shares gap down after earnings miss
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for the near and medium term: Q3 2026 to $(0.65) from $(0.51), Q4 to $(0.68) from $(0.53), fiscal 2026 to $(2.45) from $(1.99), and fiscal 2027 to $(2.11) from $(1.72). The cuts suggest slower progress toward profitability, even though the firm retained its Buy rating.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source